Tamura Yukinori, Kaji Hiroshi
Department of Physiology and Regenerative Medicine, Kinki University Faculty of Medicine, Japan.
Clin Calcium. 2013 Jun;23(6):847-52.
Parathyroid hormone (PTH) is clinically used as therapeutic agent for osteoporosis in Japan. However, the mechanisms for bone anabolic action of PTH are not fully understood. Recently, numerous studies suggest that PTH enhances bone formation through the suppression of sclerostin, DKK1 and sFRP1, inhibitors of Wnt-β-catenin signal. Moreover, we identified Tmem119 as new osteoblast differentiation factor, which is involved in an increase inβ-catenin level by PTH in osteoblasts. Further understanding of Wnt-β-catenin signaling in the bone anabolic action by PTH may lead to the development of novel bone anabolic agent.
甲状旁腺激素(PTH)在日本临床上被用作治疗骨质疏松症的药物。然而,PTH促进骨合成代谢作用的机制尚未完全阐明。最近,大量研究表明,PTH通过抑制硬化蛋白、DKK1和sFRP1(Wnt-β-连环蛋白信号的抑制剂)来增强骨形成。此外,我们鉴定出跨膜蛋白119(Tmem119)是新的成骨细胞分化因子,它参与PTH诱导成骨细胞中β-连环蛋白水平的升高。进一步了解PTH在骨合成代谢作用中的Wnt-β-连环蛋白信号传导,可能会促成新型骨合成代谢药物的开发。